OBJECTIVE Numerous references made clear that triphala is revered as a multiuse therapeutic and perhaps even panacea historically.Nevertheless,the protective mechanism of triphala on cardio-cerebral vascular diseases(...OBJECTIVE Numerous references made clear that triphala is revered as a multiuse therapeutic and perhaps even panacea historically.Nevertheless,the protective mechanism of triphala on cardio-cerebral vascular diseases(CCVDs)remains not comprehensive understanding.Hence,a network pharmacology-based method was suggested in this study to address this problem.METHODS This study was based on network pharmacology and bioinformatics analysis.Information on compounds in herbal medicines of triphala formula was acquired from public databases.Oral bioavailability as well as drug-likeness were screened by using absorption,distribution,metabolism,and excretion(ADME)criteria.Then,components of triphala,candidate targets of each component and known therapeutic targets of CCVDs were collected.Compound-target gene and compounds-CCVDs target networks were created through network pharmacology data sources.In addition,key targets and pathway enrichment were analyzed by STRING database and DAVID database.Moreover,we verified three of the key targets(PTGS2,MMP9 and IL-6)predicted by using Western blotting analysis.RESULTS Network analysis determined 132 compounds in three herbal medicines that were subjected to ADME screening,and 23 compounds as well as 65 genes formed the principal pathways linked to CCVDs.And 10 compounds,which actually linked to more than three genes,are determined as crucial chemicals.Core genes in this network were IL-6,TNF,VEGFA,PTGS2,CXCL8,TP53,CCL2,IL-10,MMP9 and SERPINE1.And pathways in cancer,TNF signaling path⁃way,neuroactive ligand-receptor interaction,etc.related to CCVDs were identified.In vitro experiments,the results indi⁃cated that compared with the control group(no treatment),PTGS2,MMP9 and IL-6 were up-regulated by treatment of 10μg·L^-1 TNF-α,while pretreatment with 20-80 mg·L^-1 triphala could significantly inhibit the expression of PTGS2,MMP9 and IL-6.With increasing Triphala concentration,the expression of PTGS2,MMP9 and IL-6 decreased.CON⁃CLUSION Complex components and pharmacological mechanism of triphala,and obtained some potential therapeutic targets of CCVDs,which could provide theoretical basis for the research and development of new drugs for treating CCVDs.展开更多
Aim YiQiFuMai Powder Injection is a well-known traditional Chinese medicine formula that has been used extensively in clinical treatment of cardio-cerebral ischemic diseases in China. However, the mechanisms under-lyi...Aim YiQiFuMai Powder Injection is a well-known traditional Chinese medicine formula that has been used extensively in clinical treatment of cardio-cerebral ischemic diseases in China. However, the mechanisms under-lying its clinical efficacy remain unknown. In this study, a network pharmacology approach was employed to identify the YiQiFuMai Powder Injection＇s potential pathways and targets against cardio-cerebral ischemia. The target-path- way interaction network clustered the signaling pathways based on high degree nodes of the drug-target network. The potential protein targets presented in the highly scored clustered pathways were the key network hubs and concentrated on one or limited functional signaling pathways amenable to experimental verification. Twelve main functional annota- tion clusters and main signaling pathways for YiQiFuMai Powder Injection were established by Biocarta analysis, in- eluding the NF-KB signaling pathway, the MAPKinase signaling pathway and the mTOR-signaling pathway and so on. YiQiFuMai Powder Injection is hypothesized to target multiple proteins with a high degree and betweenness of net- work. In addition, the most related pathways were also confirmed in tumor necrosis factor-alpha （TNF-oL） induced human vascular endothelial cell line EA. hy926 by Western blot. This study elucidates the systematic network and pathway analysis of multi-targets in YiQiFuMai Powder Injection. The results provide the possible mechanisms for its mode of action against cardio-cerebral ischemic diseases and may also reveal new clues for its potential application in the inflammatory diseases or tumors.展开更多
Respiratory disease and cardio-cerebral vascular disease frequently occur in Anyang City. In this paper, by comparing incidence num- bers of respiratory disease and cardio-cerebral vascular disease in Anyang People＇s...Respiratory disease and cardio-cerebral vascular disease frequently occur in Anyang City. In this paper, by comparing incidence num- bers of respiratory disease and cardio-cerebral vascular disease in Anyang People＇s Hospital during 2010 -2012 with seasonal change of local tem- perature,it is found that they have obvious relationship, which has very important significance for preventing respiratory disease and cardio-cerebral vascular disease in the future.展开更多
目的探讨妇科腹腔镜手术中CO2气腹和头低脚高位（Trendelenburg体位）对高血压Ⅱ级患者血流动力学及肾脏功能的影响。方法 30例腹腔镜全子宫切除术病例,美国麻醉医师协会（American Society of Anesthesiologists,ASA）分级Ⅰ~Ⅲ级,分...目的探讨妇科腹腔镜手术中CO2气腹和头低脚高位（Trendelenburg体位）对高血压Ⅱ级患者血流动力学及肾脏功能的影响。方法 30例腹腔镜全子宫切除术病例,美国麻醉医师协会（American Society of Anesthesiologists,ASA）分级Ⅰ~Ⅲ级,分为两组,H组（n=15）：高血压组（血压160~179mm Hg/100~109mm Hg）,C组（n=15）：无高血压病对照组。观察麻醉诱导前（T0）、麻醉诱导后（T1）、气腹后平卧位（T2）、气腹后头低脚高10°位（T3）、气腹后头低脚高20°位（T4）、恢复头低脚高10°位10分钟（T5）、30分钟（T6）、60分钟（T7）、气腹解除（T8）时的收缩压、舒张压、平均动脉压、心率、心输出量、心脏指数、每搏输出量、每搏指数、每搏变异度、外周血管阻力、外周血管阻力指数、中心静脉压和呼气末二氧化碳分压,以及术前、术中1小时、术后1小时、术后3小时血清肌酐、尿素氮、β2-微球蛋白。结果 T2点H组收缩压、外周血管阻力、外周血管阻力指数、中心静脉压明显高于C组（P〈0.05）;与T2比较,T4两组收缩压、舒张压、平均动脉压、中心静脉压均升高（P〈0.05）,T3各指标差异无显著性（P〉0.05）,两组间差异无显著性（P〉0.05）;气腹后H组心输出量、心脏指数、每搏输出量、每搏指数升高与C组比较差异无显著性（P〉0.05）;气腹后H组肌酐、尿素氮、β2-微球蛋白与C组比较差异无显著性（P〉0.05）。结论气腹会导致高血压Ⅱ级患者收缩压增高,但血流动力学变化尚在可接受范围内,并未加重肾脏负担,采取Trendelenburg体位10°位比20°位循环更稳定。展开更多
基金National Natural Science Foundation of China(81603385)China Postdoctoral Science Foundation(2018M643843)+1 种基金Natural Science Foundation of Shaanxi Province(2017JM8056)Key Research and Development Foundation of Shaanxi province(2018SF-241)
文摘OBJECTIVE Numerous references made clear that triphala is revered as a multiuse therapeutic and perhaps even panacea historically.Nevertheless,the protective mechanism of triphala on cardio-cerebral vascular diseases(CCVDs)remains not comprehensive understanding.Hence,a network pharmacology-based method was suggested in this study to address this problem.METHODS This study was based on network pharmacology and bioinformatics analysis.Information on compounds in herbal medicines of triphala formula was acquired from public databases.Oral bioavailability as well as drug-likeness were screened by using absorption,distribution,metabolism,and excretion(ADME)criteria.Then,components of triphala,candidate targets of each component and known therapeutic targets of CCVDs were collected.Compound-target gene and compounds-CCVDs target networks were created through network pharmacology data sources.In addition,key targets and pathway enrichment were analyzed by STRING database and DAVID database.Moreover,we verified three of the key targets(PTGS2,MMP9 and IL-6)predicted by using Western blotting analysis.RESULTS Network analysis determined 132 compounds in three herbal medicines that were subjected to ADME screening,and 23 compounds as well as 65 genes formed the principal pathways linked to CCVDs.And 10 compounds,which actually linked to more than three genes,are determined as crucial chemicals.Core genes in this network were IL-6,TNF,VEGFA,PTGS2,CXCL8,TP53,CCL2,IL-10,MMP9 and SERPINE1.And pathways in cancer,TNF signaling path⁃way,neuroactive ligand-receptor interaction,etc.related to CCVDs were identified.In vitro experiments,the results indi⁃cated that compared with the control group(no treatment),PTGS2,MMP9 and IL-6 were up-regulated by treatment of 10μg·L^-1 TNF-α,while pretreatment with 20-80 mg·L^-1 triphala could significantly inhibit the expression of PTGS2,MMP9 and IL-6.With increasing Triphala concentration,the expression of PTGS2,MMP9 and IL-6 decreased.CON⁃CLUSION Complex components and pharmacological mechanism of triphala,and obtained some potential therapeutic targets of CCVDs,which could provide theoretical basis for the research and development of new drugs for treating CCVDs.
文摘Aim YiQiFuMai Powder Injection is a well-known traditional Chinese medicine formula that has been used extensively in clinical treatment of cardio-cerebral ischemic diseases in China. However, the mechanisms under-lying its clinical efficacy remain unknown. In this study, a network pharmacology approach was employed to identify the YiQiFuMai Powder Injection＇s potential pathways and targets against cardio-cerebral ischemia. The target-path- way interaction network clustered the signaling pathways based on high degree nodes of the drug-target network. The potential protein targets presented in the highly scored clustered pathways were the key network hubs and concentrated on one or limited functional signaling pathways amenable to experimental verification. Twelve main functional annota- tion clusters and main signaling pathways for YiQiFuMai Powder Injection were established by Biocarta analysis, in- eluding the NF-KB signaling pathway, the MAPKinase signaling pathway and the mTOR-signaling pathway and so on. YiQiFuMai Powder Injection is hypothesized to target multiple proteins with a high degree and betweenness of net- work. In addition, the most related pathways were also confirmed in tumor necrosis factor-alpha （TNF-oL） induced human vascular endothelial cell line EA. hy926 by Western blot. This study elucidates the systematic network and pathway analysis of multi-targets in YiQiFuMai Powder Injection. The results provide the possible mechanisms for its mode of action against cardio-cerebral ischemic diseases and may also reveal new clues for its potential application in the inflammatory diseases or tumors.
文摘Respiratory disease and cardio-cerebral vascular disease frequently occur in Anyang City. In this paper, by comparing incidence num- bers of respiratory disease and cardio-cerebral vascular disease in Anyang People＇s Hospital during 2010 -2012 with seasonal change of local tem- perature,it is found that they have obvious relationship, which has very important significance for preventing respiratory disease and cardio-cerebral vascular disease in the future.
文摘目的探讨妇科腹腔镜手术中CO2气腹和头低脚高位（Trendelenburg体位）对高血压Ⅱ级患者血流动力学及肾脏功能的影响。方法 30例腹腔镜全子宫切除术病例,美国麻醉医师协会（American Society of Anesthesiologists,ASA）分级Ⅰ~Ⅲ级,分为两组,H组（n=15）：高血压组（血压160~179mm Hg/100~109mm Hg）,C组（n=15）：无高血压病对照组。观察麻醉诱导前（T0）、麻醉诱导后（T1）、气腹后平卧位（T2）、气腹后头低脚高10°位（T3）、气腹后头低脚高20°位（T4）、恢复头低脚高10°位10分钟（T5）、30分钟（T6）、60分钟（T7）、气腹解除（T8）时的收缩压、舒张压、平均动脉压、心率、心输出量、心脏指数、每搏输出量、每搏指数、每搏变异度、外周血管阻力、外周血管阻力指数、中心静脉压和呼气末二氧化碳分压,以及术前、术中1小时、术后1小时、术后3小时血清肌酐、尿素氮、β2-微球蛋白。结果 T2点H组收缩压、外周血管阻力、外周血管阻力指数、中心静脉压明显高于C组（P〈0.05）;与T2比较,T4两组收缩压、舒张压、平均动脉压、中心静脉压均升高（P〈0.05）,T3各指标差异无显著性（P〉0.05）,两组间差异无显著性（P〉0.05）;气腹后H组心输出量、心脏指数、每搏输出量、每搏指数升高与C组比较差异无显著性（P〉0.05）;气腹后H组肌酐、尿素氮、β2-微球蛋白与C组比较差异无显著性（P〉0.05）。结论气腹会导致高血压Ⅱ级患者收缩压增高,但血流动力学变化尚在可接受范围内,并未加重肾脏负担,采取Trendelenburg体位10°位比20°位循环更稳定。
